A Phase 2 interventional study of HLX208 in Langerhans Cell Histiocytosis, Erdheim-Chester Disease and LCH, sponsored by Shanghai Henlius Biotech. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-08.
Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Histiocytosis, Langerhans-Cell with a site in China — 11 open to participants now, 13 under way, 1 of them phase 3. Histiocytosis, Langerhans-Cell · China.
Among the 17 studies in Histiocytosis, Langerhans-Cell with a site in China, this one is the 11th largest by planned enrollment, is the only one that started in 2021, is one of 10 in phase 2, reaches primary completion later than 1 of the 12 other live ones, and was the 5th registered.
81 studies on the registry are indexed under Histiocytosis, Langerhans-Cell; 23 are open to participants now.
Browse Histiocytosis, Langerhans-Cell studies →11 of the 17 studies in Histiocytosis, Langerhans-Cell with a site in China are open now. Recruiting first, the newest first:
West China Second University Hospital · Sites in China
Ages 0–18
West China Second University Hospital · Sites in China
Ages 0–18
West China Second University Hospital · Sites in China
Ages 0–18
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–70
Shanghai Changzheng Hospital · Sites in China
Ages 2–17
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 19 Histiocytosis, Langerhans-Cell studies recruiting now, 8 (42%) set no upper age limit and 10 (53%) stop at 75 or younger; 13 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 11 · Phase 3 1 · Phase 4 1
First in 2011; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25 is close to the median of 24 across 64 interventional studies indexed under Histiocytosis, Langerhans-Cell.
Median enrollment 40 across the 17 interventional studies. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 17 have an industry lead sponsor. The 10 most frequent:
This study is registered under Shanghai Henlius Biotech, one of the names counted as Fosun Pharma. Under that name alone:
Shanghai Henlius Biotech is the lead sponsor of 132 studies on the registry; 56 are open to participants now.
Fosun Pharma has 2 studies filed under Histiocytosis, Langerhans-Cell — fewer than ten, so there is no comparison to draw.
4 of the studies in Histiocytosis, Langerhans-Cell with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07187193Cancer Institute and Hospital, Chinese Academy of Medical SciencesEfficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCH | 2027-04-12 |
| NCT07204041Cancer Institute and Hospital, Chinese Academy of Medical SciencesEfficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH | 2027-08-01 |
| NCT06078969Shanghai Changzheng HospitalOral Prednisone in Treating LCH of Bone in Childhood and Adolescence | 2027-09-30 |
| NCT07890701Second Affiliated Hospital of Wenzhou Medical UniversityA Single-Arm,Multicenter Phase, Phase II Clinical Trial of Adebrelimab Combined With Trametinib in the Treatment of Refractory Recurrent Langerhans Cell Histiocytosis in Children and Adolescents | 2027-10-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 17 studies in Histiocytosis, Langerhans-Cell with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to assess safety, efficacy and PK in adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) given HLX208 (BRAF V600E inhibitor).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive HLX208 450mg bid po
Drug: HLX208
HLX208 450mg bid po
Also known as: BRAF V600E inhibitor
ORR
Objective response rate(assessed by independent review committee (IRC) based on the PERCIST Version 1.0)
Time frame: up to 1 year
AEs
Incidence and severity of adverse events
Time frame: up to 1 year
ORR
Objective response rate(assessed by the investigator based on the PERCIST v1.0)
Time frame: up to 1 year
ORR
Objective response rate(assessed by IRC and the investigator based on the RECIST v1.1)
Time frame: up to 1 year
DCR
Disease control rate (assessed by IRC and the investigator as per PERCIST v1.0 and RECIST v1.1 )
Time frame: up to 1 year
TTR
Time to response(assessed by IRC and the investigator as per PERCIST v1.0 and RECIST v1.1)
Time frame: up to 1 year
PFS
Progression-free survival (PFS) (assessed by IRC and the investigator as per PERCIST v1.0 and RECIST v1.1 )
Time frame: from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier),assessed up to 1 year
OS
Overall survival
Time frame: from the date of first dose until the date of death from any cause,assessed up to 1 year
Cmax
Maximum Plasma Concentration
Time frame: from the date of first dose to 85 days
Tmax
Time of Maximum Plasma Concentration
Time frame: from the date of first dose to 85 days
AUC
Area Under the Curve
Time frame: from the date of first dose to 85 days
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2021 (actual). Primary completion is estimated for Jun 2024, 30 months after the start.
Of 32 phase 2 interventional studies under Histiocytosis, Langerhans-Cell, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 55 and three quarters within 85. This study's planned 30 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BRAF V600E Inhibitor HLX208
Histiocytosis, Langerhans-Cell →